Not FDA-approved1,3Evidence: Smaller human trialsNot a single peptideBrain, nerves and sleep

Cerebrolysin1

Not a single peptide: a mixture often looked up alongside peptides.

Key takeaway

Cerebrolysin is not a single peptide but a mixture of small peptides and amino acids taken from pig brain, according to a 2023 Cochrane review. It is widely used for stroke in Russia, Eastern Europe, China and other countries.1,2 The Cochrane review of seven randomized trials in acute ischaemic stroke found that it probably makes little or no difference to death, and that it may increase non-fatal serious adverse events.2 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5

Cerebrolysin at a glance

Substance typeNot a single peptide. A 2023 Cochrane review describes Cerebrolysin as a mixture of low-molecular-weight peptides and amino acids derived from pig brain, and FDA’s substance registry records it as a structurally diverse substance.1,2
What it isA mixture of low-molecular-weight peptides and amino acids derived from pig brain, recorded by FDA’s substance registry as a structurally diverse substance also coded FPF 1070.1,2
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3
Human evidenceRandomized trials in acute ischaemic stroke, summarized in a 2023 Cochrane review of seven trials with 1,773 participants that found no benefit on death.2
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is Cerebrolysin?

Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids derived from pig brain, described as having possible nerve-protecting properties, according to the 2023 Cochrane review.2

FDA’s substance registry records it as a structurally diverse substance, not a single defined molecule, under the names Cerebrolysin and FPF 1070.1

How is Cerebrolysin thought to work?

It has been studied for a possible protective effect on nerve cells after stroke. The Cochrane review describes potential neuroprotective properties but does not establish a mechanism.2

What do human studies show?

A 2023 Cochrane review found seven randomized trials, with 1,773 participants, of Cerebrolysin or a similar product started within 48 hours of an acute ischaemic stroke.2

It concluded, with moderate certainty, that these products probably make little or no difference to death from any cause, and that Cerebrolysin probably makes little or no difference to the total number of people with serious adverse events.2

Moderate-certainty evidence also pointed to a possible increase in non-fatal serious adverse events with Cerebrolysin. The review judged the risk of bias in most trials to be unclear and noted that the maker supported three of them.2

What the evidence base contains

  • Controlled human trial A 2023 Cochrane systematic review of seven randomized trials in 1,773 people with acute ischaemic stroke (one of them testing a similar product, Cortexin), which rated the evidence on death and serious adverse events as of moderate certainty.2

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is Cerebrolysin FDA-approved?

None of the sources reviewed here reports an approval of Cerebrolysin by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list Cerebrolysin.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cerebrolysin is not among them.4,5

Timeline

  1. A Cochrane review update finds that Cerebrolysin probably has no effect on death after acute ischaemic stroke.2

What is still unknown?

Its effect on recovery and quality of life after stroke: the trials in the Cochrane review did not report death or dependence at the end of follow-up, or quality of life.2

Which components of the mixture, if any, are active, which the sources reviewed here do not establish.1,2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Cerebrolysin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Cerebrolysin are a bounded selection, not every registration or paper about Cerebrolysin. For the years before Cerebrolysin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cerebrolysin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cerebrolysin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied in clinical trials. A Cochrane review of seven randomized stroke trials with 1,773 participants found no benefit on death and a possible rise in non-fatal serious adverse events. Cerebrolysin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Cerebrolysin?

No FDA approval reported; studied in clinical trials. A Cochrane review of seven randomized stroke trials with 1,773 participants found no benefit on death and a possible rise in non-fatal serious adverse events. Cerebrolysin is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
12
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 17, 2026

    Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.↗Source date November 14, 2026
  2. Literature metadata · added November 16, 2026

    Cerebrolysin: a review of its use in dementia.↗Source date October 11, 2026
  3. Literature metadata · added November 16, 2026

    Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.↗Source date October 10, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Cerebrolysin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

47Selected dated records
52Connected citations
12Populated source years2010–2026
2/4Record lanes present

Registered human studies

Trial composition

19 of 21 selected trial records include at least one phase value; 21 of 21 include a status value in the retained structured contract.

PhasesPhase 2 6Phase 4 5Phase 3 4Not applicable 3Phase 1 3
Status at observationCompleted 15Not yet recruiting 2Recruiting 2Active, not recruiting 1Enrolling by invitation 1

A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

26 of 26 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 26Review 11Research Support, Non-U.S. Gov't 9Systematic Review 8Meta-Analysis 6Controlled Clinical Trial 2Randomized Controlled Trial 2Research Support, U.S. Gov't, Non-P.H.S. 2Case Reports 1Clinical Trial 1English Abstract 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
47

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 47 dated records

Research hub

Explore the Cerebrolysin evidence record

Open all 47 records →
47Dated records
2Evidence types
47Cited public sources
12Source years

Change ledger

Recently changed for Cerebrolysin

Open all 47 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.

PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 17, 2026
Cited source date
November 14, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT00840671

PeptideScanner retained ClinicalTrials.gov record NCT00840671 at 2026-11-16T17:33:14.861Z. Its registry update date was 2010-12-28, and PeptideScanner's reviewed identity mapping was cerebrolysin.

PeptideScanner change date
November 16, 2026
Cited source date
December 28, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00868283

PeptideScanner retained ClinicalTrials.gov record NCT00868283 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-12-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.

PeptideScanner change date
November 16, 2026
Cited source date
December 15, 2023
Evidence lane
Clinical trials

Official-source collections

Source records for Cerebrolysin

Open the full research atlas →
PubMed26

26 with attributed title, venue, publication-date, and type metadata.

  1. Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.Journal of clinical medicine · 2026 11 09
  2. Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025 12 03
  3. The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts.Neuroscience · 2025 01 19
Explore all selected literature →
ClinicalTrials.gov21

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07846488Registry update September 29, 2026 · current at observation
  2. NCT06339411Registry update August 11, 2026 · current at observation
  3. NCT04427241Registry update May 11, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span December 28, 2010 to November 14, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 47

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.↗

    PubMed lists PMID 43030876 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Cerebrolysin: a review of its use in dementia.↗

    PubMed lists PMID 19848437 in Drugs & aging as Journal Article, Review, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.↗

    PubMed lists PMID 33620612 in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology as Journal Article, Meta-Analysis, with publication-date metadata of 2021-02-23 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07846488↗

    PeptideScanner retained ClinicalTrials.gov record NCT07846488 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗

  5. Literature metadata

    Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.↗

    PubMed lists PMID 37892776 in Journal of clinical medicine as Journal Article, Review, with publication-date metadata of 2023-10-20 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06339411↗

    PeptideScanner retained ClinicalTrials.gov record NCT06339411 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗

  7. Literature metadata

    The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts.↗

    PubMed lists PMID 39832667 in Neuroscience as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-01-19 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04427241↗

    PeptideScanner retained ClinicalTrials.gov record NCT04427241 at 2026-11-16T17:33:14.861Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗

  9. Literature metadata

    [Cerebrolysin for acute ischemic stroke].↗

    PubMed lists PMID 23805635 in Vestnik Rossiiskoi akademii meditsinskikh nauk as Journal Article, Review, with publication-date metadata of 2013 (year precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy.↗

    PubMed lists PMID 41349847 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Journal Article, Review, with publication-date metadata of 2025-12-03 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT06052787↗

    PeptideScanner retained ClinicalTrials.gov record NCT06052787 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT05821075↗

    PeptideScanner retained ClinicalTrials.gov record NCT05821075 at 2026-11-16T17:33:14.861Z. Its registry update date was 2025-07-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Cerebrolysin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Cerebrolysin for acute ischaemic stroke (2023) · PMID 37818733 ↗

    Cochrane Database of Systematic Reviews · Official source · Source checked November 16, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026